RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR-T therapy aims to tackle Hard-to-Treat multiple myeloma
Disease control Recruiting nowThis phase 3 trial is testing a new CAR-T cell therapy called arlo-cel against standard treatments for adults with multiple myeloma that has come back or stopped responding to previous therapies. About 440 participants will receive either arlo-cel or a standard regimen. The study…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE3 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for Tough-to-Treat blood cancer: phase 3 trial launched
Disease control Recruiting nowThis study tests a new drug called F182112 against standard treatments in 261 adults with multiple myeloma that has returned or stopped responding to prior therapies. The goal is to see if the new drug can delay cancer growth longer than usual care. Participants must have already…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE3 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Double-Barreled CAR-T attack on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage study tests a new cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has returned or not responded to treatment and has spread outside the bone marrow. The main goal is to check the safety of this ap…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Double-Barreled CAR-T cells take aim at Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase trial is testing a new type of immune cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to treatment and has spread to other parts of the body. The main goal is…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Phase: PHASE1 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC